Valepotriate
Based on 1 Customer Validation
Valepotriate can be isolated from Valeriana jatamansi Jones, has anti-epileptic and anti-cancer activities.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.40%
- No. CAS: 18296-44-1
- Fòrmula: C22H30O8
- Peso molecular:422.47
-
Almacenamiento:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Covalent Screening Library
HY-L036
-
Lipid Compound Library
HY-L043
-
Terpenoids Library
HY-L056
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Food-Sourced Compound Library
HY-L094
-
Anti-Cancer Natural Product Library
HY-L107
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Human Metabolite Library
HY-L123
-
Cysteine Targeted Covalent Library
HY-L153
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Miao Ethnicity Medicine Compound Library
HY-L190
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Mongolian Medicine Compound Library
HY-L238
-
Natural Product Diversity Scaffold Library
HY-L245
-
Mass Spectrometry Natural Product Library
HY-L262
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
3.7 μM
Compound: 21
|
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
|
[PMID: 19245261] |
| Bel-7402 | IC50 |
6.1 μM
Compound: 21
|
Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay
|
[PMID: 19245261] |
| HCT-8 | IC50 |
1.8 μM
Compound: 21
|
Cytotoxicity against human HCT8 cells after 24 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 24 hrs by MTT assay
|
[PMID: 19245261] |
| HeLa | IC50 |
2.5 μM
Compound: 1
|
Inhibition of hemagglutininin-tagged HIV1 Rev protein nuclear export in human HeLa cells assessed as protein localization after 12 hrs by indirect fluorescent antibody technique
Inhibition of hemagglutininin-tagged HIV1 Rev protein nuclear export in human HeLa cells assessed as protein localization after 12 hrs by indirect fluorescent antibody technique
|
[PMID: 20207540] |
| HeLa | IC50 |
2.5 μM
Compound: 1
|
Inhibition of hemagglutininin-tagged HIV1 Rev protein nuclear export in human HeLa cells assessed as localization by indirect fluorescent antibody technique
Inhibition of hemagglutininin-tagged HIV1 Rev protein nuclear export in human HeLa cells assessed as localization by indirect fluorescent antibody technique
|
[PMID: 20643553] |
| PC-3M | IC50 |
1.6 μM
Compound: 21
|
Cytotoxicity against human PC3M cells after 24 hrs by MTT assay
Cytotoxicity against human PC3M cells after 24 hrs by MTT assay
|
[PMID: 19245261] |
| PC-3M | IC50 |
1.7 μM
Compound: 6
|
Cytotoxicity against human PC3M cells by MTT assay
Cytotoxicity against human PC3M cells by MTT assay
|
[PMID: 18052324] |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 18296-44-1
-
Appearance Oil
-
Peso molecular 422.47
-
Fòrmula C22H30O8
-
Color Light brown to brown
-
SMILES
O=C(CC(C)C)O[C@@H]1[C@]2(CO2)[C@]([C@@H]3OC(CC(C)C)=O)([H])C(C(COC(C)=O)=CO3)=C1
-
Synonyms
Valtrate
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvente y solubilidad
DMSO : 100 mg/mL (236.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.92 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (5.92 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (273 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Yan YY, et al. A novel derivative of valepotriate inhibits the PI3K/AKT pathway and causes Noxa-dependent apoptosis in human pancreatic cancer cells. Acta Pharmacol Sin. 2020 Feb 11. [Content Brief]
[2]. Wu A, et al. Anti-epileptic Effects of Valepotriate Isolated from Valeriana jatamansi Jones and Its Possible Mechanisms. Pharmacogn Mag. 2017 Jul-Sep;13(51):512-516. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3670 mL | 11.8352 mL | 23.6703 mL | 59.1758 mL |
| 5 mM | 0.4734 mL | 2.3670 mL | 4.7341 mL | 11.8352 mL | |
| 10 mM | 0.2367 mL | 1.1835 mL | 2.3670 mL | 5.9176 mL | |
| 15 mM | 0.1578 mL | 0.7890 mL | 1.5780 mL | 3.9451 mL | |
| 20 mM | 0.1184 mL | 0.5918 mL | 1.1835 mL | 2.9588 mL | |
| 25 mM | 0.0947 mL | 0.4734 mL | 0.9468 mL | 2.3670 mL | |
| 30 mM | 0.0789 mL | 0.3945 mL | 0.7890 mL | 1.9725 mL | |
| 40 mM | 0.0592 mL | 0.2959 mL | 0.5918 mL | 1.4794 mL | |
| 50 mM | 0.0473 mL | 0.2367 mL | 0.4734 mL | 1.1835 mL | |
| 60 mM | 0.0395 mL | 0.1973 mL | 0.3945 mL | 0.9863 mL | |
| 80 mM | 0.0296 mL | 0.1479 mL | 0.2959 mL | 0.7397 mL | |
| 100 mM | 0.0237 mL | 0.1184 mL | 0.2367 mL | 0.5918 mL |
Valepotriate Related Classifications
HY-N0718 Related Classifications
Powered by Bioz